Search

Displaying results 4641 - 4650 of 10000 in total
  1. Drug

    Tilbroquinol

    go.drugbank.com/drugs/DB13222
    Approved

    In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis. … Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467].

  2. Drug

    WL-1002

    go.drugbank.com/drugs/DB05346
    Experimental

    WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.

  3. Drug

    99mTc-glucarate

    go.drugbank.com/drugs/DB05810
    Investigational

    99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.

  4. Drug

    D-glyceraldehyde 3-phosphate

    go.drugbank.com/drugs/DB02263
    Experimental

    An aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.

  5. Drug

    Choline alfoscerate

    go.drugbank.com/drugs/DB04660
    Investigational

    A component of phosphatidylcholines (lecithins), in which the two hydroxy groups of glycerol are esterified with fatty acids. … (From Stedman, 26th ed) It counteracts the effects of urea on enzymes and other macromolecules. [PubChem]

    Synonyms: sn-3-GPC, sn-Glycero-3-phosphocholine
  6. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain). … NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

  7. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. … HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine.

  8. Drug

    LY-2624803

    go.drugbank.com/drugs/DB15092
    Investigational

    LY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject).

  9. Drug

    Pipendoxifene

    go.drugbank.com/drugs/DB05414
    Investigational

    ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. … Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment

  10. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine … N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.

    Synonyms: N-Methyl nicotineamide, 3-(N-Methylcarbamoyl)pyridine